Frontline Therapy in Chronic Lymphocytic Leukemia

Background: The treatment landscape of chronic lymphocytic leukemia (CLL) has tremendously evolved in the last decades, thanks to the introduction of more effective therapies. Summary: Frontline therapy for patients with CLL includes chemoimmunotherapy (CIT) and pathway inhibitors (PIs) (i.e., bruton tyrosine kinase inhibitors and BCL2 inhibitors); the latter has proved to be more effective than CIT mainly in patients with high-risk features (e.g., TP53 aberrations and unmutated IGHV) with acceptable toxicity. Combinations of PIs are playing the protagonist role as frontline therapy for CLL. Key Messages: In this article, the management of treatment-naïve patients with CLL is discussed.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Frontline Therapy in Chronic Lymphocytic Leukemia ; volume:147 ; number:1 ; year:2024 ; pages:49-61 ; extent:13 ; Acta haematologica ; 147, Heft 1 (2024), 49-61 (gesamt 13)

Contributors, Places and Time

• Creator: Arguello-Tomas, Miguel ; Albiol, Nil ; Moreno, Carol

Further information

• DOI: 10.1159/000534730
• URN: urn:nbn:de:101:1-2024020723135883086243
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:30 AM CEST